Investing & Markets

Make better decisions with investing tips, technical analysis, market commentary, and more

Personal Finance

Make more, save more, spend smarter, and keep more of what you earn

Business News

Stock market news & analysis


Stem Cells Versus Aging, Fountain of Youth (BTIM, GERN, ACTC)

By BioHealth Investor on 03/16/2010 – 10:00 am PDTLeave a Comment

How many movies and legends are based upon eternal youth?  Hundreds or thousands for sure.  BioTime, Inc. (NYSE Amex: BTIM) is seeing a massive surge of interest today after the company announced a “Peer-Reviewed Scientific Publication on the Reversal of the Developmental Aging of Normal Human Cells.”

The company is a small-cap biotechnology company (approximately $250 million) pursuing the development and marketing of products in the field of stem cells and regenerative medicine.   The article was released online today in the peer-reviewed journal Regenerative Medicine ahead of the print publication showing that the aging of human cells can be reversed.  The company noted that this “may have significant implications for the development of new classes of cell-based therapies targeting age-related degenerative disease.”

BioTime and its collaborators demonstrate the successful reversal of the developmental aging of normal human cells according to the article.  The full article at Future Medicine is here.

BioTime is is led by Dr. Michael West as CEO.  He was the Founder of Geron Corporation (NASDAQ: GERN), where he served until 1998.  From 1998 to 2007 he was President and Chief Scientific Officer of Advanced Cell Technology Inc. (OTC: ACTC).  Dr. West also gave a CNBC video here just this morning.

Also noted was that the aged differentiated cells became young stem cells capable of regeneration and transforming adult human cells back to a state very similar to embryonic stem cells.  Does it come without exception or without differences?  No.

Still, this is sending BioTime shares through the roof.  Usually we see just over 100,000 shares trade hands.  Today we have 3.3 million shares traded at 12:50 PM EST and BioTime’s stock is up 28% at $7.43 today.


Related Articles:

  1. FDA response for ACT anticipated on January 31 (NASDAQ:ACTC)
  2. OncoVista’s AdnaGen Test (OTC:OVIT)
  3. Entest Biomedical COPD Treatments (OTC:ENTB)
  4. Geron Will Re-initiate Clinical Trials (NASDAQ:GERN)
  5. CytRx’s Seeking Destruction Of Cancer Cells (NASDAQ:CYTR)

Comments are closed.